Famotidine

• A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults with Post COVID-1… Not authorised
  2023-504087-42-00 Phase III 1 country Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocio…
• A study to investigate the safety and efficacy of mRNA-3927 in participants with genetically confirmed propionic acidemia Recruiting
  2022-502910-10-00 Phase I (FiH) 4 countries Moderna Inc.
• A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) ( PREVAIL ) Recruiting
  2024-519345-30-00 Phase III 11 countries Biogen Idec Research Limited
• KEYMAKER U01 Sub-Study E Signal-finding study to test investigational agents with pembrolizumab in combination with chemotherapy in newly di… Recruiting
  2023-509234-19-00 Phase II 5 countries Merck Sharp & Dohme LLC
• Phase 1/2 study of mRNA-3705 in participants with Isolated MMA (Extension Study). Recruiting
  2022-501997-20-00 Phase I (FiH) 3 countries Moderna Inc.
• Study of Combination Therapies in Esophageal Cancer Recruiting
  2023-505189-26-00 Phase I/II 3 countries Merck Sharp & Dohme LLC
• Phase II proof-of-concept, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of plitidepsin in adults w… Ended
  2024-516378-31-00 Phase II 1 country Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocio…
• Study of SKB264 to treat participants with advanced non-small cell lung cancer alone or as a combination treatment Ended
  2023-507270-41-00 Phase II 2 countries Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants with… Ended
  2023-508697-28-00 Phase I (FiH) 7 countries Denali Therapeutics Inc.
• A Phase 3 Study of NTLA 2001 in participants with amyloidosis with cardiac muscle disease. Halted
  2023-507220-23-00 Phase III 14 countries Intellia Therapeutics Inc.
• A Phase 1/2, adaptive, open-label, single ascending dose to multiple ascending dose study to evaluate the safety, tolerability, pharmacokine… Ended
  2022-502963-39-00 Phase I (FiH) 4 countries Moderna Therapeutics Inc.
• Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy (EXPA… Ended
  2023-503830-27-00 Phase II 3 countries Allogene Therapeutics Inc.
• Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA2) Ended
  2022-501927-25-00 Phase II 2 countries Allogene Therapeutics Inc.
• A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) Ended
  2023-508422-95-00 Phase I/II 1 country Synthorx Inc.
• FAMODREP : Interest of Famotidine in Reducing Endothelial Expression of P-selectin in Children With Sickle Cell Disease: Pilot Study, Single… Ended
  2022-502144-12-00 Phase IV 1 country Assistance Publique Hopitaux De Paris
• A dose-finding study to evaluate mRNA-3210 in participants with phenylketonuria Ended
  2023-506963-32-00 Phase I (FiH) 3 countries Moderna Therapeutics Inc.
• Study of SKB264 in patients with advanced and hard-to-treat cancers who have not responded well to standard treatments. Ended
  2023-508700-38-00 Phase II 2 countries Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.

Showing 1–17 of 17 trials